Skip to Content
Merck
  • Oxidized porous silicon particles covalently grafted with daunorubicin as a sustained intraocular drug delivery system.

Oxidized porous silicon particles covalently grafted with daunorubicin as a sustained intraocular drug delivery system.

Investigative ophthalmology & visual science (2013-01-17)
Jay Chhablani, Alejandra Nieto, Huiyuan Hou, Elizabeth C Wu, William R Freeman, Michael J Sailor, Lingyun Cheng
ABSTRACT

To test the feasibility of covalent loading of daunorubicin into oxidized porous silicon (OPS) and to evaluate the ocular properties of sustained delivery of daunorubicin in this system. Porous silicon was heat oxidized and chemically functionalized so that the functional linker on the surface was covalently bonded with daunorubicin. The drug loading rate was determined by thermogravimetric analysis. Release of daunorubicin was confirmed in PBS and excised rabbit vitreous by mass spectrometry. Daunorubicin-loaded OPS particles (3 mg) were intravitreally injected into six rabbits, and ocular properties were evaluated through ophthalmic examinations and histology during a 3-month study. The same OPS was loaded with daunorubicin using physical adsorption and was evaluated similarly as a control for the covalent loading. In the case of covalent loading, 67 ± 10 μg daunorubicin was loaded into each milligram of the particles while 27 ± 10 μg/mg particles were loaded by physical adsorption. Rapid release of daunorubicin was observed in both PBS and excised vitreous (~75% and ~18%) from the physical adsorption loading, while less than 1% was released from the covalently loaded particles. Following intravitreal injection, the covalently loaded particles demonstrated a sustained degradation of OPS with drug release for 3 months without evidence of toxicity; physical adsorption loading revealed a complete release within 2 weeks and localized retinal toxicity due to high daunorubicin concentration. OPS with covalently loaded daunorubicin demonstrated sustained intravitreal drug release without ocular toxicity, which may be useful to inhibit unwanted intraocular proliferation.

MATERIALS
Product Number
Brand
Product Description

Daunorubicin hydrochloride, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Daunorubicin hydrochloride, ≥90% (HPLC)
Sigma-Aldrich
Daunorubicin hydrochloride, meets USP testing specifications